Dr. Michael Har-Noy Describes the Development of AlloStim™ – A New Cancer Drug

23 Jul

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., a biotech company in Israel, has developed a unique biologic, AlloStim™, which stimulates a patient’s immune response to attack tumor cells. This enables a patient’s own immune system to scavenge and destroy all metastatic cells. AlloStim™ is made from T-Stim cells, which are created using unique, patented methods.

Dr. Michael Har-Noy says that T-Stim cells are produced outside the body in a bioreactor. T-Stim cells are produced from T-cell precursors isolated from the blood of normal donors. Typically, 100 million of these cells can be made from one normal donor’s blood. After a nine day culture process, approximately 10 billion T-Stim cells can be manufactured. There is no need to match donor to recipient, as AlloStim™ is intentionally mis-matched to the patient receiving it.

To manufacture T-Stim cells, Dr. Michael Har-Noy says that naïve CD4 cells are cultured on a medium coated with anti-CD3 and anti-CD28 monoclonal antibodies. These antibodies, as well as cell-to-cell contact, cause activation and maturation of the CD4 cells. The cells multiply at least 100-fold during the culture process, enabling one donor to produce enough T-Stim cells for 100 patients.

Dr. Michael Har-Noy indicates that in this environment, the T-Stim cells mature into memory CD4 cells that produce very high amounts of IL-2, IFN-g and TNF-a when activated. Additionally, T-Stim cells express high amounts of CD40L and FasL (a transmembrane protein) on the cell surface. CD40L interacts with the patient’s innate CD40 immune cells and stimulates these cells to produce Th1 cytokines that kill malignant cells. The FasL enables the patient’s immune cells to kill tumors.

Dr. Michael Har-Noy adds that in order to produce the Mirror EffectTM, the name Immunovative Therapies has given to this novel method of immune manipulation, the T-Stim cells need activation prior to infusion into the patient. T-Stim cells are activated with monoclonal antibody-coated beads that are then filtered out before infusion. “AlloStim™” is the name given to the formulated and activated T-Stim cells.

Dr. Michael Har-Noy says that he is preparing to test AlloStim™ in a Phase II/III double-blind randomized trial of pre-treated metastatic breast cancer patients.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: